Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05290597
Title A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Innovent Biologics (Suzhou) Co. Ltd.
Indications

Advanced Solid Tumor

lymphoma

Therapies

IBI363

Age Groups: senior | adult
Covered Countries


No variant requirements are available.